Flyer

Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 18
  • Journal CiteScore: 5.91
  • Journal Impact Factor: 4.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Ana Lisica

Department of Medical Biochemistry, Uppsala University, Sweden

Publications
  • Mini Review   
    Clinical Application of Epithelial Mesenchymal Transition Markers: Novel Insights from Proteomics
    Author(s): Ana Lisica*

    Clinical markers may be derived from our improving understanding of the molecular processes underpinning the epithelial-to-mesenchymal transition (EMT). Despite the fact that EMT drivers have not yet become viable candidate markers in the clinical context, they may become more sensitive and specific if they are associated with other recognised clinical markers. Mass spectrometrybased platforms enable the analysis of numerous samples for the expression of EMT candidate indicators, which may aid in the accurate diagnosis of disorders or the efficient monitoring of treatment. This review emphasises proteomic methods used to clarify the distinctions between mesenchymal and epithelial cancers and explains how they might be utilised to target discovery and validation. The existence of metastatic cells in distant organs is a serious worry in the treatment of tumour patients. Human malignanci.. View More»

    DOI: 10.36648/2172- 0479.13.11.269

    Abstract HTML PDF